To this end, one strategy will be to identify minimal biologically active doses of CREB inhibitors in combination with other drugs, to enable rational drug schedules that maximize tumor-selective killing while minimizing host toxicity (Koh et al, 2018; Koh, 2022). This evidence concerns the gene CREB1 and neoplasm.